News | December 17, 2025
AstraZeneca wins EU nod for self-administered lupus drug Saphnelo
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
US FDA approval based on NEURO-TTRansform Phase III results
Subscribe To Our Newsletter & Stay Updated
